BioSpace News Archive

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 42nd annual J.P. Morgan Healthcare Conference in San Francisco.

OPKO Health, Inc. announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.

InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has been awarded a $943,000 grant to support recruitment and to investigate biomarkers in its Phase 2 clinical trial in patients with bulbar-onset ALS (NCT05508074).

HilleVax, Inc. announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST.

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., a clinical-stage biotechnology company committed to advancing oligonucleotide therapies, with a primary focus on achieving a functional cure for chronic hepatitis B infection, announced that Dr. Will Wei has joined the company as Head of CMC, SVP.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 11:15 a.m. PT.

Keros Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, at a public offering price of $40.00 per share.

Nalu Medical Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain, announced today the closing of a $65 million equity financing.

Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’) today announced that the Philippines Food & Drug Administration has authorised the initiation of a Phase I-II clinical trial of CoronaTcP™1, Emergex’s T cell-priming set-point product, designed to be broadly effective against disease caused by Betacoronaviruses, including SARS-CoV-1, as well as known and emerging variants of SARS-CoV-2.